Search - tctmd.com

Displaying 361 - 380 of 412

Sort: Relevancy | Date

News Daily News

La Actualización de las Directrices sobre la Dieta Cambia el Centro de Atención a Patrones Alimenticios Saludables

Todd Neale

January 18, 2016

News Industry News

Renova Therapeutics expands robust gene therapy intellectual property portfolio for cardiovascular and metabolic disease treatments

January 03, 2016

News Daily News

AHA Scientific Statement Highlights Sex Disparities in CV Risk Among Diabetic Patients

L.A. McKeown

December 09, 2015

News Industry News

New Publication Featuring GlycoMark® Test Highlights Association of Hyperglycemic Excursions With Cardiovascular Outcomes And Mortality

November 17, 2015

News Industry News

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

September 18, 2015

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

News Conference News ESC 2015

TECOS: No Differences in Heart Failure Outcomes When Sitagliptin Added to Usual Care in Diabetics

Yael L. Maxwell

August 31, 2015

News Conference News ESC 2015

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

L.A. McKeown

August 31, 2015

News Industry News

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

August 31, 2015

News Conference News ESC 2015

FREEDOM Substudy: CABG, PCI Outcomes Affected by Baseline BP

Yael L. Maxwell

August 30, 2015

News Industry News

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

August 20, 2015

News Industry News

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

August 20, 2015

News Daily News

Los Niveles Altos de Troponina T Pronostican Malos Resultados en Pacientes Con Diabetes Tipo 2 y Cardiopatía Estable

Todd Neale

August 17, 2015

News Daily News

High Troponin T Foretells Poor Outcomes in Patients With Type 2 Diabetes, Stable Heart Disease

Todd Neale

August 17, 2015

News Daily News

Novel Antisense Inhibitor Cuts High Triglyceride Levels

August 13, 2015

News Daily News

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Yael L. Maxwell

August 12, 2015

News Industry News

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

June 22, 2015

News Industry News

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

June 09, 2015

Advertisement

La Actualización de las Directrices sobre la Dieta Cambia el Centro de Atención a Patrones Alimenticios Saludables

Renova Therapeutics expands robust gene therapy intellectual property portfolio for cardiovascular and metabolic disease treatments

AHA Scientific Statement Highlights Sex Disparities in CV Risk Among Diabetic Patients

New Publication Featuring GlycoMark® Test Highlights Association of Hyperglycemic Excursions With Cardiovascular Outcomes And Mortality

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

TECOS: No Differences in Heart Failure Outcomes When Sitagliptin Added to Usual Care in Diabetics

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

FREEDOM Substudy: CABG, PCI Outcomes Affected by Baseline BP

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

Los Niveles Altos de Troponina T Pronostican Malos Resultados en Pacientes Con Diabetes Tipo 2 y Cardiopatía Estable

High Troponin T Foretells Poor Outcomes in Patients With Type 2 Diabetes, Stable Heart Disease

Novel Antisense Inhibitor Cuts High Triglyceride Levels

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content